Attenuation of O6-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in Jurkat cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 294, Issue 2, 2000, Pages 664-671

  D'Atri, Stefania ^a   Graziani, Grazia ^b   Lacal, Pedro Miguel ^a   Nisticò, Vittoria ^b   Gilberti, Sara ^b   Faraoni, Isabella ^b   Watson, Amanda J ^c   Bonmassar, Enzo ^a   Margison, Geoffrey P ^c  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CROSS LINKING; CYTOTOXICITY; DNA REPAIR; DRUG ACTIVITY; DRUG EFFECT; ENZYME INACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MESSENGER RNA SYNTHESIS; METHYLATION; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE PAIR MISMATCH; CISPLATIN; DACARBAZINE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; JURKAT CELLS; KINETICS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RNA, MESSENGER;

EID: 0033943310     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aamadal S, Gerard B, Bohman T and D'Incalci M (1992) Sequential administration of dacarbazine and fotemustine in patient with disseminated malignant melanoma: An effective combination with unexpected toxicity. Eur J Cancer 213:447-450.
2. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, Sartori C and Bruckner HW (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: Clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276-6282.
3. Anthoney DA, MacIlwrath AJ, Gallagher WM, Edlin ARM and Brown R (1996) Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 56:1374-1381.
4. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJ, Brampton M and Stevens MF (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913.
5. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P and Brampton MH (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484-488.
6. Chomczynski P and Sacchi A (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
7. 6-benzylguanine Cancer Res 53:4750-4753.
8. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E and Jiricny J (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334-341.
9. 6-alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 15: 279-292.
10. 6-Benzylguanine and its role in chemotherapy. Clin Cancer Res 3:837-847.
11. Drummond JT, Anthoney A, Brown R and Modrich P (1996) Cisplatin and Adriamycin resistance are associated with MutL and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271:19645-19648.
12. Garbe C (1993) Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3:291-299.
13. 6-methylguanine-DNA methyltransferase gene. Cancer Res 56:2029-2032.
14. Iwamoto KS, Mizuno T, Ito T, Tsuyama N, Kyozumi S and Seyama T (1996) Gain of function p53 mutations enhance alteration of T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res 56:3862-3865.
15. Jiricny J (1996) Mismatch repair and cancer, in Genetic Instability in Cancer (Lindahl T ed) pp 47-68, Cancer Surveys, Cold Spring Harbor University Press, Cold Spring Harbor, NY.
16. + human tumor cells. Carcinogenesis (Lond) 16:2255-2257.
17. 6-alkylguanine-DNA alkyltransferase by antitumor triazene compounds. J Pharmacol Exp Ther 279:416-422.
18. 6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation Cancer 66:331-336.
19. Lee SM, Margison GP, Woodcock AA and Thatcher N (1993b) Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 67:1356-1360.
20. 6-alkylguanine-DNA-alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69:452-456.
21. 6-alkylguanine-DNA-alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 67:216-221.
22. Lemaire MA, Schwartz A, Rahmouni AR and Leng M (1985) Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cisdiamminedichloroplatinum(II) and DNA. Proc Natl Acad Sci USA 88:1982-1985.
23. Levati L, Marra G, Lettieri T, D'Atri S, Vernole P, Tentori L, Lacal PM, Pagani E, Bonmassar E, Jiricny J and Graziani G (1998) Mutation of the mismatch repair gene hMSH2 in a human T-cell leukemia line tolerant to methylating agents. Genes Chromosomes Cancer 23:159-166.
24. 6-(hetarylmethyl)guanines having basic rings in the side-chain. J Med Che 41:5265-5271.
25. Modrich P (1997) Strand-specific mismatch repair in mammalian cells. J Biol Chem 272:24727-24730.
26. 6-methylguanine-DNA methyltransferase. Mutat Res DNA Repair 293:119-132.
27. 6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: A phase I trial. Cancer Res 52:2456-2459.
28. 6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50:6119-6129.
29. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167-223.
30. Piccioni D, D'Atri S, Papa G, Caravita T, Franchi A, Bonmassar E and Graziani G (1995) Cisplatin increases sensitivity of human leukaemic blasts to triazene compounds. J Chemotherapy 7:224-228.
31. 6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro. Cancer Res 51: 1581-1585.
32. Reed E and Kohn KW (1990) Cisplatin and platinum analogs, in Cancer Chemotherapy Principles and Practice (Chabner BA and Collins J, eds) pp 465-490, J. B. Lippincott, Philadelphia.
33. 6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB10-277, a new DTIC analogue. Cancer Chemoth Pharm 31:240-246.
34. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, Newton C, Lunt E, Fizames C and Lavelle F (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846-5852.
35. Untch M, Sevin BU, Perras JP, Angioli R, Untch A, Hightower RD, Koechli O and Averette HE (1994) Evaluation of paclitaxel (Taxol), cisplatin and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol 53:44-49.
36. 6-alkylguanine-DNA alkyltransferase in HeLa cell by cisplatin. Carcinogenesis 10:1681-1684.
37. 6-Alkylguanine-DNA alkyltransferase assays, in Cytotoxic Drug Resistance Mechanisms (Brown R and Boeger-Brown U eds) pp 167-178, Humana Press, Totowa, NJ.
38. Woll PJ, Crowther D, Johnson PWM, Soukop M, Harper PG, Harris M, Brampton MH and Newlands ES (1995) Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 72:183-184.
39. 6-benzylguanine. Cancer Res 59:1514-1519.
40. Zlotogorski C and Erickson LC (1984) Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts. Carcinogenesis 5:83-87.